ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: As a second-generation tyrosine kinase inhibitor that allows for a superior deep molecular response, Nilotinib is approved for the first-line treatment of BCR-ABL-positive chronic granulocytic leukemia [42].